Trabodenoson_product_DataBase

Bioactivity

Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma[1].

Invitro

Trabodenoson treatment significantly increaseS MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression[1].

In Vivo

Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation)[1].Topical trabodenoson significantly upregulates nestin expression in the ONH of induced eyes compared with vehicle-treated no-induced eyes[2].Trabodenoson-treated eyes have significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. RGC counts are higher in Trabodenoson-treated eyes compared to vehicle (74% versus 47% of the contralateral eye)[2]. Animal Model:

Name

Trabodenoson

CAS

871108-05-3

Formula

C15H20N6O6

Molar Mass

380.36

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Guorong Li, et al. Trabodenoson, an Adenosine Mimetic With A1 Receptor Selectivity Lowers Intraocular Pressure by Increasing Conventional Outflow Facility in Mice. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):383-392. [2]. Yan Guo, et al. Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION). Transl Vis Sci Technol. 2019 Dec 20;8(6):47.

PeptideDB

Trabodenoson

CAS: 871108-05-3 F: C15H20N6O6 W: 380.36